Younger UK children to benefit from new dose of nasal spray allergy drug - Pharmaceutical Technology

The MHRA’s approval of a lower dose of EURneffy means more children will have a needle-free option to treat anaphylaxis. The MHRA’s approval of a lower dose of EURneffy means more children will have a needle-free option to treat anaphylaxis. Anaphylaxis, a severe allergic reaction, typically occurs in response to food, insect stings, or medications. Credit: sergey0506/Shutterstock.com. Younger children in the UK will now have a needle-free option to treat serious allergic reactions after the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new dose of ALK-Abelló’s EURneffy. The new lower dose version of EURneffy – an adrenaline…

Source: Pharmaceutical Technology